A sardonic Senate cabinet inform on the reserve of the diabetes drug Avandia contains errors, dubious conclusions and deficient information, GlaxoSmithKline wrote in the central response, that the association posted online this morning.
"GSK stands at the back of the reserve of Avandia," the drug builder wrote in the response. "The association rejects any allegations of concealing reserve inform or behaving inappropriately on interest of patients."
The Senate inform is only the ultimate storm from critics who contend the drug, that was authorized in 1999, can means heart attacks or alternative health problems. Some lawmakers and physicians are job for the Food and Drug Administration to hearing the reserve and lift it off the market.
GSK pronounced it welcomes a "fair hearing of the companys record" and the clinical interpretation that proves Avandia is protected and effective.
The drug has seen disappearing sales given 2007 when a little distinguished physicians began criticizing it. But the drug still brought GSK $1.2 billion in worldwide sales last year.
GSK is one of the Triangles largest employers, with about 5,000 workers at the North American domicile in Research Triangle Park and a bureau in Zebulon that packages drugs, together with Avandia.
Download GSKs 30-page reply to the Senate cabinet online here.
No comments:
Post a Comment